Xeris raises year-end cash guidance to $65-70M, tightens 2023 revenue to $155-165M

Xeris Biopharma Holdings, Inc.

Year-end cash, equivalents, and short-term investments guided to $65-70M (up from $55-65M).
Full-year 2023 total revenue guidance tightened to $155-165M from $145-165M.
Received $6M milestone payment from Amgen for subcutaneous TEPEZZA formulation success.
Company reaffirms cash flow breakeven in Q4 2023; net cash outflow H2 expected ~$11-16M.
Q3 2023 earnings call scheduled for November 9, 2023 at 8:30 a.m. ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.